Receptor Tyrosine Kinase Treatment Market Size

  • Report ID: 3626
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Receptor Tyrosine Kinase Treatment Market Size

Receptor Tyrosine Kinase Treatment Market size was valued at USD 66.18 billion in 2024 and is set to exceed USD 175.7 billion by 2037, registering over 7.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of receptor tyrosine kinase treatment is evaluated at USD 74.7 billion.

The growth of the market can be attributed by growing cases of cancer all around the world. According to the World Health Organization, nearly 10 million deaths, or nearly one in six deaths, were caused by cancer in 2020, making it the top cause of death globally. Hence the demand for targeted therapies are growing. Targeted therapy includes tyrosine kinase inhibitors (TKIs). A targeted therapy lessens the harm done to healthy cells by locating and attacking particular cancer cell types. Hence, the adoption of TKIs is growing extensively. Further, among this the receptor tyrosine kinase treatment is popular. Cell growth and survival are two important processes that are regulated by receptor tyrosine kinase (RTK) activity. But it has been demonstrated that dysregulation of RTK correlates with the onset and spread of many malignancies, and it has been discovered in a variety of tumors. As a result, RTK has gained popularity as a therapeutic target.

Additionally, there has been growing initiatives taken to spread awareness regarding the diagnosis and availability of cancer treatment. Also, governments are initiating their efforts and making healthcare facilities accessible to people. Further, since there has been growing prevalence of cancer, the R&D activities are also on boost. Moreover, the market for receptor tyrosine kinase treatment is being driven by the existence of patient support programmes. A lot of public and private organizations are concentrating on offering monetary and medical support for the therapy of numerous cancer symptoms. As a result, a large number of patients are receiving the necessary care, which is growing the patient base. These initiatives aid patients in sticking to their treatment plans.


Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3626
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of receptor tyrosine kinase treatment is evaluated at USD 74.7 billion.

The receptor tyrosine kinase treatment market size was valued at USD 66.18 billion in 2024 and is set to exceed USD 175.7 billion by 2037, registering over 7.8% CAGR during the forecast period i.e., between 2025-2037. The market growth is driven by surge in prevalence of obesity, growing investment in healthcare, clinical approval of kinase inhibitors, and others.

North America industry is likely to dominate majority revenue share of 40% by 2037, driven by high prevalence of cancer, increasing R&D activities with tyrosine kinase inhibitors, and presence of prominent companies in the region.

The major players in the market are Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Eton Bioscience, Inc., GlaxoSmithKline plc, Merck KGaA, AstraZeneca, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample